Small Molecules in Oncology
en Limba Engleză Paperback – 4 mai 2012
Preț: 1659.39 lei
Preț vechi: 1746.73 lei
-5%
Puncte Express: 2489
Carte disponibilă
Livrare economică 16-30 noiembrie
Livrare prin curier în România Termenul estimat este afișat lângă disponibilitate.
Transport gratuit pentru acest produs Plată online sau ramburs, în funcție de opțiunile comenzii.
Retur gratuit în 14 zile Comandă securizată și suport în română.
Specificații
ISBN-13: 9783642261459
ISBN-10: 3642261450
Pagini: 256
Ilustrații: XVI, 238 p.
Dimensiuni: 155 x 235 x 15 mm
Greutate: 0.39 kg
Ediția:2010
Editura: Springer
Locul publicării:Berlin, Heidelberg, Germany
ISBN-10: 3642261450
Pagini: 256
Ilustrații: XVI, 238 p.
Dimensiuni: 155 x 235 x 15 mm
Greutate: 0.39 kg
Ediția:2010
Editura: Springer
Locul publicării:Berlin, Heidelberg, Germany
Public țintă
Professional/practitionerCuprins
Protein kinase inhibitors.- Imatinib Mesylate.- Erlotinib.- Axitinib (AG-013736).- Lapatinib.- Sorafenib.- Sunitinib.- Dasatinib.- Nilotinib.- Bosutinib.- Epigenetic modifiers.- Decitabine.- 5-Azacytidine/Azacitidine.- Cell cycle inhibitors.- Bortezomib.- Temsirolimus.- Danusertib (formerly PHA-739358) – A Novel Combined Pan-Aurora Kinases and Third Generation Bcr-Abl Tyrosine Kinase Inhibitor.- BI_2536 - Targeting the Mitotic Kinase Polo-Like Kinase 1 (Plk1).- Other novel agents.- Imetelstat (GRN163L) - Telomerase-Based Cancer Therapy.- GDC-0449 - Targeting the Hedgehog Signaling Pathway.
Textul de pe ultima copertă
Extensive research into the molecular mechanisms of cancer disease has heralded a new age of targeted therapy. In malignant cells, key proteins that are crucial to tumor growth and survival are now being targeted directly with rationally designed inhibitors. Apart from monoclonal antibodies, small molecule therapeutics such as oncogenic protein kinase inhibitors are attracting a vast amount of investigational attention. This textbook, written by acknowledged experts, provides a broad overview of the small molecules currently used for the treatment of malignant diseases and discusses interesting novel compounds that are in the process of clinical development to combat cancer.
Recenzii
“The book is recommended for healthcare professionals, scientists, and students in medical and scientific fields. In 25 well-written chapters, experts in their fields of research describe in great detail 12 compounds currently in clinical use for the treatment of hematological malignancies, and 13 compounds applicable to specific mutation-containing malignancies or aimed at interfering with the microenvironment (such as angiogenesis). … This book provides important practical information on a wide variety of novel small molecule-based treatment approaches.” (George Somlo, Doody's Book Reviews, April, 2015)